US Pharma MarketingRegeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Regeneron has ponied up $125 million in cash and an equity investment in Parabilis Medicines to join forces on a new type of antibody-drug conjugate that could have better luck binding to tricky target sites.
Source: FierceBiotech